scholarly journals Recombinant activated factor VII for diffuse alveolar hemorrhage in microscopic polyangiitis

2012 ◽  
Vol 22 (2) ◽  
pp. 130 ◽  
Author(s):  
S Jasuja ◽  
G Sagar ◽  
SK Mandal ◽  
M Sahoo
Keyword(s):  
Microscopic Polyangiitis ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii

Parenteral use of recombinant activated factor VII during diffuse alveolar hemorrhage secondary to leptospirosis

2009 ◽  
Vol 36 (3) ◽  
pp. 555-556 ◽  
Author(s):  
Alexis Tatopoulos ◽  
Delphine Herbain ◽  
Céline Kazmierczak ◽  
Pierre-Edouard Bollaert ◽  
Sébastien Gibot
Keyword(s):  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii

scholarly journals Failure of Recombinant Activated Factor VII in Treatment of Diffuse Alveolar Hemorrhage due to Cryoglobulinemic Vasculitis

2014 ◽  
Vol 2014 ◽  
pp. 1-3
Author(s):  
Dania Khoulani ◽  
Bharat Rao ◽  
Ammar Khanshour ◽  
Philip Kuriakose ◽  
Lenar Yessayan
Keyword(s):  
Case Reports ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Factor Vii ◽  
Small Vessel Vasculitis ◽  
Cryoglobulinemic Vasculitis ◽  
Recombinant Activated Factor Vii ◽  
Randomized Controlled ◽  
Activated Factor Vii ◽  
Life Threatening

Diffuse alveolar hemorrhage (DAH) is a serious complication of the small vessel vasculitis syndromes and carries a high mortality. Recombinant activated factor VII (rFVIIa) is used to treat bleeding in patients with hemophilia and antibodies to factor VIII or IX. It is increasingly being used in life-threatening hemorrhage in a variety of other settings in which conventional therapy is unsuccessful. Randomized controlled trials of rFVIIa in DAH are lacking. However, several case reports have described a complete or sustained control of DAH using rFVIIa after patients failed to respond to medical treatment. There are no case reports in the literature describing the use or the failure of rFVIIa in DAH associated with cryoglobulinemic vasculitis. We here report the failure of rFVIIa to control DAH in a patient with CD5+ B-cell non-Hodgkin’s lymphoma and cryoglobulinemic vasculitis.

scholarly journals Treatment of diffuse alveolar hemorrhage secondary to lupus erythematosus with recombinant activated factor VII administered with a jet nebulizer

2014 ◽  
Vol 2 (1) ◽  
Author(s):  
Raúl Carrillo Esper ◽  
Isis EspinozadelosMonteros Estrada ◽  
Teresa de la Torre León ◽  
Agustín OmarRosales Gutiérrez ◽  
Jorge ArturoNava López
Keyword(s):  
Lupus Erythematosus ◽  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Factor Vii ◽  
Recombinant Activated Factor Vii ◽  
Activated Factor Vii ◽  
Jet Nebulizer

Use of Activated Factor VII in Patients with Diffuse Alveolar Hemorrhage: A 10 Years Institutional Experience

Lung ◽  
2015 ◽  
Vol 193 (3) ◽  
pp. 375-379 ◽  
Author(s):  
Vikas Pathak ◽  
Judy Kuhn ◽  
Don Gabriel ◽  
Jennifer Barrow ◽  
J. Charles Jennette ◽  
...  
Keyword(s):  
Diffuse Alveolar Hemorrhage ◽  
Alveolar Hemorrhage ◽  
Factor Vii ◽  
Activated Factor Vii ◽  
Institutional Experience
Sign in / Sign up

Export Citation Format

Share Document